Novo Nordisk ready to roll with Russia plant; Teva, Novartis to unveil MS studies at neurology meeting;

@FiercePharma: North Carolina shuts down animal drug compounder. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Here's Baxter release on recall of 8 saline lots, 4 dextrose, 3 Lactated Ringer's Injection. Release | Follow @EricPFierce

> Novo Nordisk ($NVO) opened its new diabetes drug manufacturing plant in Russia, focusing on modern insulins in two types of injectors. Release

> Teva Pharmaceutical ($TEVA) is rolling out new data on its longer-acting formula of Copaxone at the American Academy of Neurology meeting this week. Release

> Novartis ($NVS) plans to unveil new data and analyses on its multiple sclerosis meds, including its blockbuster Gilenya pill, at the American Academy of Neurology meeting this week. Release

> Roche's ($RHHBY) anti-inflammatory drug Actemra is now under testing as a treatment for Type 1 diabetes. Report

> Mylan's ($MYL) proposed $29 billion buyout of Perrigo ($PRGO) could push its credit rating into junk territory if it's not careful about financing the deal with debt, analysts said. Report

> Novo Nordisk parent company Novo A/S tapped Bjarne Graven Larsen as its new CFO to replace the retiring Thorkil Christensen. Report

> Sales of medically important human antibiotics to the U.S. meat industry grew by 20% between 2009 and 2013, according to an FDA analysis. Report

Medical Device News

@FierceMedDev: FDA announces LuSys Labs' recall of its unapproved Ebola diagnostic. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: NIH awards $11M to develop tests for drug-resistant bacteria. More from FierceDiagnostics | Follow @EmilyWFierce

> Qualcomm extends its Life2Net reach in deal with Cerner. Story

> ReCor Medical reels in $15M to recharge renal denervation efforts. Article

Biotech News

@FierceBiotech: Big Pharma partner: Check. Crossover round: Check. Hot tech: Check. IPO? Report | Follow @FierceBiotech

@JohnCFierce: Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact. News | Follow @JohnCFierce

> After PhIII odyssey, the FDA finally gives Medicines Co a thumbs-up for cangrelor. Article

> FDA clears the way for Arrowhead's hep B treatment, with a caveat. Story

> Drew Fromkin takes the helm at Langer's Blend Therapeutics. Item

Animal Health News

> Zoetis innovation lab seeks to create electronic health record for every U.K. farm animal. Report

> Jennie-O-Turkey plant struck by bird flu. Story

> Mylan seeks entry into animal health via $29B bid for Perrigo. Item

> North Carolina shuts down animal drug compounder. Article

> Chicago outbreak of dog flu has authorities pitching Merck vaccine. More

Biotech IT News

> Rise of Big Data prompts peer review rethink at Nature Biotechnology. Item

> Early user of Venter's DNA synthesizer reports saving time, money. Report

> BioXcel adds Takeda to its roster of A-list clients. More

> Eisai's new research unit taps Genomics for analysis support. Story

> Peking University inks Medidata deal as China inches into eClinical era. Article

Suggested Articles

The lawsuit is part of a years-long battle between the Cochrane Collaboration and Roche around Tamiflu's use against pandemic influenza.

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.